Treatment Catalogue

Nuclear medicine therapies in India — in one place.

Ten theranostic therapies. Eight radionuclides. Three indication families. One centre, one team. Everything we administer at Fortis Memorial Research Institute, Sector 44, Gurugram — explained, costed, and bookable.

10
Therapies offeredFrom standard-of-care to emerging protocols
8
RadionuclidesLu, Ac, Tb, Y, Ra, I, Ga, Pb
3
Indication familiesProstate, NETs, liver-directed & emerging
The principle

If the scan shows it, the therapy can treat it.

Theranostics is built on a single, elegant idea: diagnose and treat with the same molecular target. A diagnostic radiotracer (such as 68Ga-PSMA-11 or 68Ga-DOTATATE) binds to a marker on the cancer cell and shows where the disease is. The therapeutic counterpart binds to the same marker — and delivers radiation directly into the tumour.

This is not chemotherapy. It is not external-beam radiation. It is targeted, receptor-specific radiation delivered as an outpatient infusion every 6 to 8 weeks. The therapies below are grouped by indication. Each links to a complete clinical page with protocol, eligibility, outcomes data, and cost.

Indication 01

Prostate Cancer — PSMA-targeted.

For metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen is the most reliable theranostic target identified to date. Three radioisotopes, three different particle physics, one disease — sequenced as the disease evolves.
Beta · Standard of care
177Lu
PSMA THERAPY
[Image: clinical photograph — Lu-177 PSMA therapy administration]
Lutetium-177 · β beta emitter

Lu-PSMA Therapy

The most-evidenced radioligand therapy in mCRPC. VISION trial: 15.3 vs 11.3 months overall survival. Available in Indian-source and German-source variants.

4–6 cycles6–8 weeks apart
₹ 75K–5.85Lper cycle
View full protocol
Alpha · Salvage
225Ac
ALPHA PSMA
[Image: vial close-up — Ac-225 alpha emitter therapy]
Actinium-225 · α alpha emitter

Alpha PSMA

Higher linear energy transfer than Lu-177 with a ~50–100 μm tissue range. The salvage line for patients who have progressed on Lu-177 PSMA, or for bulky-disease cases needing deeper kill.

100 kBq/kgper cycle dose
₹ 13–15Lper cycle
View full protocol
Emerging · Beta + Auger
161Tb
TB-161 PSMA
[Image: scientific schematic — Tb-161 emission profile]
Terbium-161 · β + Auger electrons

Tb-161 PSMA

Combined beta and Auger emission means dual-scale dosimetry — killing both single tumour cells and clusters. FMRI is among the first centres in India administering Tb-161.

7.4 GBqper cycle
₹ 5.17–7.5Lper cycle
View full protocol
Indication 02

Neuroendocrine & rare endocrine tumours.

For somatostatin-receptor-positive neuroendocrine tumours, mIBG-positive pheochromocytoma, paraganglioma and neuroblastoma. Theranostics extends progression-free survival by years in well-selected NET patients — NETTER-1 reported 28.4 vs 8.4 month median PFS.
Beta · Standard of care
177Lu
PRRT
[Image: PRRT infusion suite — FMRI Sector 44]
Lu-177 DOTATATE · β beta emitter

PRRT

Peptide Receptor Radionuclide Therapy — the established standard of care for somatostatin-receptor-positive NETs. NETTER-1 trial: 79% PFS at 20 months vs 11% control.

4 cyclesevery 8 weeks
₹ 5.70Lper cycle (intl.)
View full protocol
Alpha · Salvage
225Ac
ALPHA PRRT
[Image: post-therapy SPECT/CT imaging — Ac-225 DOTATATE]
Ac-225 DOTATATE · α alpha emitter

Alpha PRRT

For NETs progressing on Lu-177 DOTATATE, or with bulky liver-dominant disease. Higher LET per disintegration for refractory cases retaining DOTATATE-PET uptake.

100 kBq/kgper cycle dose
₹ 15.22Lper cycle (intl.)
View full protocol
Beta · Specialty
131I
mIBG THERAPY
[Image: I-131 mIBG isolation ward at FMRI]
Iodine-131 mIBG · β beta emitter

I-131 mIBG

For mIBG-avid pheochromocytoma, paraganglioma, neuroblastoma and refractory carcinoid. High-dose capability on site with appropriate shielded inpatient suites.

100–200 mCiper cycle
On requestcase-by-case pricing
View full protocol
Indications 03 · 04 · 05

Liver-directed, bone-targeted, and pan-cancer.

Y-90 TARE for HCC and liver metastases. Ra-223 for bone-only mCRPC. And the FAPI family — fibroblast activation protein inhibitors — extending theranostics to sarcomas, GI cancers, and pancreatic cancer where no PSMA or DOTATATE target exists.
Beta · Liver-directed
90Y
TARE
[Image: TARE interventional procedure — cath lab]
Yttrium-90 microspheres · β beta

Y-90 TARE

Trans-arterial radioembolisation for hepatocellular carcinoma, metastatic liver disease and cholangiocarcinoma. Catheter-delivered microspheres deliver radiation directly to liver tumours.

3.0 GBqtypical dose
On requestcase-by-case
View full protocol
Alpha · Bone-targeted
223Ra
RA-223
[Image: skeletal radiotracer uptake — bone scintigraphy]
Radium-223 dichloride · α alpha

Ra-223

For mCRPC with bone-dominant disease and no visceral metastases. Calcium-mimic bone targeting with alpha emission — ALSYMPCA trial showed survival benefit and reduced skeletal events.

50 kBq/kgper cycle
6 cyclesmonthly
View full protocol
Emerging · Pan-cancer
177Lu
FAPI THERAPY
[Image: FAPI-PET scan demonstrating tumour stroma uptake]
Lu-177 FAPI · β beta emitter

Lu-177 FAPI

FAPI targets fibroblast activation protein on cancer-associated fibroblasts — expressed in sarcomas, pancreatic, gastric, ovarian, breast and HCC. Extends theranostics into cancers without PSMA or DOTATATE targets.

Emergingcompassionate use
On requestindividualised
View full protocol
Emerging · High-energy
90Y
Y-90 FAPI
[Image: bulky sarcoma pre/post Y-90 FAPI — placeholder]
Y-90 FAPI · β high-energy beta

Y-90 FAPI

Higher energy and longer tissue range than Lu-177 FAPI — suited to bulky tumours where deeper penetration is therapeutically advantageous. Particularly relevant in advanced sarcomas and HCC.

Emergingcompassionate use
On requestindividualised
View full protocol
Future protocols
212Pb
UPCOMING
[Image: research lab — emerging radionuclide development]
Lead-212 · α alpha (emerging)

Upcoming theranostics

Pb-212 PSMA and Pb-212 PRRT under active international development. 10.6-hour half-life alpha emitter — advantageous logistics. We're tracking trials and preparing protocols for early access.

In developmenttrial-stage
2026–27expected access
View pipeline
Diagnostics

First, the scan.

Every theranostic therapy begins with a PET-CT to confirm the molecular target. 35+ scan types on Siemens Biograph Vision — PSMA, DOTATATE, FDG, FAPI, Amyloid, Exendin — same-week availability.

Book a PET-CT scan
Consultation

Talk to Dr. Sen's team.

A 20-minute online consultation reviews your imaging, prior treatment lines, and disease pattern — and produces a written treatment plan with eligibility, sequencing, and cost.

Book consultation
How we decide

Choosing between therapies.

The right theranostic therapy depends on three things, in this order. We work through them with you, in writing, before any cycle is scheduled.

01

The molecular target

Confirmed by the matching diagnostic PET scan. PSMA-PET for prostate cancer, DOTATATE-PET for NETs, FAPI-PET for FAP-expressing cancers. Uptake intensity on the scan correlates directly with therapy response.

02

The disease pattern

Tumour burden, organ involvement, prior treatment lines and pace of progression. Bone-dominant disease may favour Ra-223. Bulky liver disease may favour Y-90 or alpha emitters. Refractory disease often escalates from beta to alpha therapy.

03

Your organ function

Kidneys, liver and bone marrow set the dose ceiling. We use individualised dosimetry — not formula-based dosing — calibrated to creatinine clearance, haematology and prior radiation exposure. Well-titrated doses are a deliberate philosophy.

Pricing & transparency

No commission. No tourism markup.

We publish indicative pricing for every therapy in INR and USD — in the open, because aggregators won't. A written quote, calibrated to your case, arrives within 24 working hours of enquiry. Therapy fees only — FMRI imaging and inpatient charges billed separately.

See full pricing matrix All 10 therapies · INR & USD
Request a written quote WhatsApp · 24-hour turnaround
Therapy calendar

Real cadence, real slots.

Lu-177 cycles run Fridays. Y-90 TARE on Wednesdays. Ac-225 and Tb-161 alternate fortnights. mIBG and Ra-223 by clinical priority. The next six weeks below.

Lu-177 (PSMA + PRRT) Ac-225 (PSMA + α-PRRT) Tb-161 PSMA Y-90 TARE I-131 mIBG Ra-223
Week 21· May
19–25 May
Lu-177 PSMA
Fri 22 May
Y-90 TARE
Wed 20 May
Ac-225 PSMA
Fri 22 May · fortnight
Reserve →
Week 22· May
26 May–1 Jun
Lu-177 DOTATATE
Fri 29 May
Y-90 TARE
Wed 27 May
Tb-161 PSMA
Fri 29 May · fortnight
Reserve →
Week 23· Jun
2–8 Jun
Lu-177 PSMA
Fri 5 Jun
Y-90 TARE
Wed 3 Jun
Ac-225 α-PRRT
Fri 5 Jun · fortnight
Reserve →
Week 24· Jun
9–15 Jun
Lu-177 DOTATATE
Fri 12 Jun
Y-90 TARE
Wed 10 Jun
Tb-161 PSMA
Fri 12 Jun · fortnight
Reserve →
Week 25· Jun
16–22 Jun
Lu-177 PSMA
Fri 19 Jun
Y-90 TARE
Wed 17 Jun
Ac-225 PSMA
Fri 19 Jun · fortnight
Reserve →
Week 26· Jun
23–29 Jun
Lu-177 DOTATATE
Fri 26 Jun
Y-90 TARE
Wed 24 Jun
Tb-161 PSMA
Fri 26 Jun · fortnight
Reserve →

I-131 mIBG and Ra-223 scheduled by clinical priority. Daily slots Mon–Sat. Please call ahead.

In her own words

Theranostics, explained.

Radioisotope therapy — best explained, for patients.

Dr. Ishita B. Sen · Senior Director, Nuclear Medicine, FMRI Gurugram
46+ episodes on YouTube
FAQ

Frequently asked questions.

Nuclear medicine therapy uses small amounts of radioactive substances (radiopharmaceuticals) attached to molecules that selectively bind cancer cells. The radiation is delivered directly to the tumour cells, sparing healthy tissue.

It is also called radionuclide therapy, radioligand therapy, or theranostic therapy when paired with diagnostic imaging on the same molecular target.

Chemotherapy acts on all rapidly dividing cells, including healthy bone marrow, gut lining and hair follicles — which causes widespread side effects.

Theranostics delivers radiation only to cells expressing a specific molecular target (such as PSMA for prostate cancer or somatostatin receptors for NETs). Side effects are dramatically fewer, and the therapy is given as an outpatient infusion every 6 to 8 weeks.

At our centre we treat:

Metastatic castration-resistant prostate cancer — Lu-177 and Ac-225 PSMA, plus Ra-223 for bone-only disease.
Neuroendocrine tumours — Lu-177 DOTATATE PRRT and Ac-225 alpha-PRRT.
Pheochromocytoma, paraganglioma, neuroblastoma — I-131 mIBG therapy.
HCC and liver metastases — Y-90 TARE.
Sarcomas, pancreatic, gastric, ovarian, breast cancer — emerging FAPI therapy.

The choice is driven by three factors, in order.

First, the molecular target on the patient's cancer, confirmed by a PET scan with the matching diagnostic tracer. Second, the disease pattern — tumour burden, organ involvement, and prior treatment lines. Third, organ function, including kidneys, liver and bone marrow.

Dr. Sen's team prepares a written treatment plan after consultation, with sequencing and cost outlined upfront.

Yes. All listed therapies are administered at our centre at Fortis Memorial Research Institute, Sector 44, Gurugram.

Both Indian-source and German-source Lu-177 are available. Pricing differs significantly between the two sources — Indian-source options make advanced theranostic therapy accessible at a fraction of international costs.

Coverage is improving. Several major Indian private insurers now cover Lu-177 PSMA, Lu-177 DOTATATE PRRT, and Y-90 TARE as established therapies. Coverage for emerging therapies like Ac-225 and Tb-161 varies by insurer and policy.

Our coordinators help prepare the clinical documentation insurers typically require — please WhatsApp us for a pre-authorisation pack.

Most theranostic therapies are administered as 4 to 6 cycles spaced 6 to 8 weeks apart, totalling 6 to 10 months of treatment.

Each cycle is typically a same-day outpatient infusion. International patients usually combine each cycle with a 2 to 3 night stay in Gurugram.

IS
[Image: Dr. Sen portrait]
Reviewed By

Dr. Ishita B. Sen

MBBS · DRM · DNB (Nuclear Medicine) · 30+ years in nuclear oncology

Director and Head, Department of Nuclear Medicine and Molecular Imaging, Fortis Memorial Research Institute. Visiting fellowships at Memorial Sloan Kettering Cancer Center and the University of Marburg. Past President, Association of Nuclear Medicine Physicians of India. Co-author on published Indian protocols for Lu-177 and Ac-225 therapy.

Full profile
Last updated: 15 May 2026

Medical disclaimer All physicians and researchers profiled on this page hold appointments at the Department of Nuclear Medicine & Molecular Imaging, Fortis Memorial Research Institute, Gurugram. Theranostic Physicians Private Limited (TPPL) is the clinical practice entity through which they consult and treat patients. Treatment outcomes vary by individual case; clinical decisions are made on the basis of complete medical records, current imaging, and a multidisciplinary review.